Childhood Cancer Clinical Trials Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Childhood Cancer Clinical Trials Act (H.R. 5647) is a legislative proposal introduced in the 118th Congress aimed at addressing issues related to clinical trials for childhood cancer. The bill was referred to the House Subcommittee on Health but has since failed or expired without further legislative action. Specific details about the bill's provisions, objectives, or mechanisms are not available in the provided source data.
H.R. 5647 sought to impact childhood cancer clinical trials but did not advance beyond subcommittee referral and ultimately failed or expired in the 118th Congress.
- The bill is titled the Childhood Cancer Clinical Trials Act and was introduced in the House of Representatives during the 118th Congress.
- It was referred to the Subcommittee on Health on December 17, 2024, but no further legislative progress was recorded.
- The bill's full text and official summary are not available, limiting detailed analysis of its content and intended impact.
['Children diagnosed with cancer who may participate in clinical trials', 'Healthcare providers and researchers involved in pediatric oncology clinical trials', 'Potentially federal health agencies overseeing clinical trial regulations and funding']
['Lack of available bill text and summary limits understanding of implementation requirements and funding mechanisms', 'Unclear oversight and enforcement provisions due to missing detailed legislative language', 'Potential costs and resource allocation for clinical trial infrastructure and support are unknown']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not advance further and is recorded as failed or expired as of December 19, 2024. The policy area is health, specifically focusing on childhood cancer clinical trials, a subject of ongoing legislative interest.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased focus on pediatric oncology research infrastructure if the bill had provisions supporting clinical trials', "Possible influence on future legislative efforts addressing childhood cancer clinical trials due to the bill's introduction and referral", 'Heightened awareness among stakeholders about the need for legislative action in childhood cancer clinical trials']
The absence of an official summary and full bill text limits transparency and public oversight. Monitoring future legislative proposals in this policy area is important to ensure clear communication of provisions, funding, and enforcement mechanisms. The bill's failure or expiration without further action highlights the need for accessible legislative documentation to facilitate informed public and stakeholder engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.